Centercon Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.11 M
- Paid Up Capital ₹ 0.11 M
- Company Age 14 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.50 M
- Revenue Growth 1.34%
- Profit Growth 44.67%
- Ebitda 1215.65%
- Net Worth 381.82%
- Total Assets -11.14%
About Centercon Pharmaceutical
Centercon Pharmaceutical Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 July 2010 and has a history of 14 years and seven months. Its registered office is in Nagpur, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.11 M and a paid-up capital of Rs 0.11 M.
The company has closed loans amounting to ₹1.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pramod Suple and Anil Sonar serve as directors at the Company.
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24297MH2010PTC205473
- Company No.
205473
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jul 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Centercon Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pramod Suple  | Director | 08-Mar-2013 | Current |
| Anil Sonar | Director | 14-Jul-2010 | Current |
Financial Performance of Centercon Pharmaceutical.
Centercon Pharmaceutical Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 1.34% increase. The company also saw a substantial improvement in profitability, with a 44.67% increase in profit. The company's net worth Soared by an impressive increase of 381.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Centercon Pharmaceutical?
In 2015, Centercon Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹1.50 M
Charges Breakdown by Lending Institutions
- Bank Of India : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 May 2011 | Bank Of India | ₹1.50 M | Satisfied |
How Many Employees Work at Centercon Pharmaceutical?
Unlock and access historical data on people associated with Centercon Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Centercon Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Centercon Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
